Surveillance decision

We will not update the guideline at this time.

Reason for the decision

We found 25 studies through surveillance of this guideline.

This included new evidence that supports current recommendations on:

  • Use and timing of mast cell tryptase testing in the anaphylaxis diagnostic pathway.

  • Patient information after a suspected anaphylactic reaction.

We also found new evidence that was considered to have no impact on current recommendations, including:

  • Duration of observation after a suspected anaphylactic reaction.

  • Assessment and the decision to refer after a suspected anaphylactic reaction.

We did not find any new evidence related to models of care for the diagnosis of anaphylaxis. Generally, topic experts thought that an update was not needed.

Other clinical areas

We did not find any new evidence in areas not covered by the original guideline.

Equalities

No equalities issues were identified during the surveillance process.

Overall decision

After considering all the new evidence and views of topic experts, we decided that no update is necessary for this guideline.

See how we made the decision for further information.

Commentary on selected new evidence

With advice from topic experts we did not select any studies for further commentary.


This page was last updated: 10 November 2016